Phase 4 N=4 Treatment of CNS Sarcoidosis With H.P. Acthar Gel
CNS Sarcoidosis
Primary: Karnofsky Performance Status (KPS) Score — 76.67; 76.67 score on a scale — p=1.0
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=15 Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
Pulmonary Sarcoidosis · Lung Function
Primary: Change in Absolute FVC From Baseline to Post Completion of 8 Weeks of Antibiotic Therapy. — 2.61 liters
Phase 2 N=17 Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: Change in Inflammation Marker — -43; 7 mg/L
Phase 2 N=29 Trial of Antimycobacterial Therapy in Sarcoidosis
Sarcoidosis
Primary: Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions — -8.4…
N/A N=9 Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
Ocular Sarcoidosis · Panuveitis · Anterior Uveitis
Primary: Percentage of Patients With Clinically Significant Improvement in Visual Acuity — 3 Participants
Phase 2 N=64 Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Neuropathy of Sarcoidosis
Primary: Change in Corneal Nerve Fiber Area — -64.3; 533.8; 203.8; -170.0 µm^2
Phase 2 N=97 Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
Sarcoidosis; Antimycobacterial Therapy
Primary: Change in Percent Predicted Absolute Forced Vital Capacity (FVC) in Participants With Pulmonary Sarcoidosis, Comparing Baseline With Performance After Completion of 16…
Phase 2 N=50 Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study
Sarcoidosis
Primary: Forced Vital Capacity (FVC) — 0.07; -0.07 liters
Phase 2 N=55 Atorvastatin to Treat Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Primary: The Steroid Sparing Period — 301; 257 days
N/A N=17 The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Bronchoalveolar Lavage (BAL) and Peripheral Blood Mononuclear Cells (PBMC) TNF-α Levels — 40767; 39938; 45176; 25671 pg/ml
Phase 2 N=15 Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
Sarcoidosis
Primary: Number of Participants Without Sarcoidosis Flare (Flare-Free Survival) — 2; 7 Participants
Phase 2 N=219 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
Phase 2 N=33 Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma
CNS Lymphoma · CNS Brain Cancer · Non-Hodgkin's Lymphoma
Primary: Number of Participants Evaluated for Toxicity — 33 Participants
N/A N=15 Radiosurgery and Avastin for Recurrent Malignant Gliomas
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
Phase 2 N=40 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Change Between Baseline and Week 24 in Pulmonary Function as Measured by Spirometry — -1.90; 0.52 Percent Predicted Forced Vital Capacity
N/A N=26 Immunotherapy of the Paraneoplastic Syndromes
Paraneoplastic Syndromes
Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months
Phase 2 N=62 Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Change in Percent Predicted FVC From Baseline to 16 Weeks of Treatment — -0.48; 1.02 Percent predicted — p=0.1804
Phase 4 N=55 Acthar Gel in Participants With Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Primary: DBT: Number of Participants in Each Category of Assessment Based on Forced Vital Capacity (FVC), a Pulmonary Function Test Parameter at Week 24 — 10; 7; 12; 12…
Phase 2 N=173 A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
Sarcoidosis
Primary: Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 16 — 2.02; 1.15; -0.15 percent of predicted FVC — p=0.543
Phase 4 N=15 d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: 68Ga-DOTATATE Uptake With Cardia Sarcoidosis (CS)
Phase 1 N=13 The Maraviroc Central Nervous System (CNS) Study
HIV Infections
Primary: CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) — 1.01 ratio
N/A N=9 Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma
Brain Tumor
Primary: Percent Decrease in Central Nervous System Bioavailability of Sulfasalazine — 17; 23; 28; 5 percentage of change
N/A N=52 Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Lymphoma
Primary: Total Number of Participants Who Experienced Acute Treatment Related Adverse Events — 52 Participants
Phase 2 N=40 High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
B-cell Lymphomas
Primary: Event-free Survival — 16 Participants
Phase 3 N=356 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 28.5; 25.3 months — p=0.2853
Phase 1 N=5 Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
Sarcoidosis, Pulmonary · Sarcoidosis Lung · Sarcoidosis
Primary: Number of Participants With 50% Reduction in Corticosteroid Requirement — 3 Participants
Phase 3 N=12 Tadalafil for Sarcoidosis Associated Pulmonary Hypertension
Pulmonary Hypertension
Primary: 6 Minute Walk Distance — 419.1; 418.1; 436.5; 377.1 meters — p=0.68
N/A N=17 Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
Sarcoidosis
Primary: Number of Participants Characterized by Abnormal or Negative Uptake — 4; 3; 6 Participants
Phase 2 N=1 JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
Kohlmeier Degos Disease With Neurologic Involvement · Kohlmeier-Degos Disease
Primary: Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib — 1; 0; 0 Participants
N/A N=18 Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
HIV Infections
Primary: Change in CSF Concentrations of Neopterin After 12 Weeks — 0.1; 0.3 nmol/L